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Background: Several studies have investigated MRI breast cancer screening in women at increased risk,
but little is known about their preferences. In this study, experiences, expectations and preferences for
MRI and mammography were evaluated among women undergoing screening with MRI and/or
mammography in the randomized FaMRIsc trial.
Methods: A 17-item questionnaire was sent to 412 women in the FaMRIsc trial. Participants were aged 30
e55 years, had a 20% cumulative lifetime risk, but no BRCA1/2 or TP53 gene variant, and were screened
outside the population-based screening program. Women received annual mammography (mammog-
raphy-group), or annual MRI and biennial mammography (MRI-group). We asked whether women trust
the screening outcome, what they consider as (dis)advantages, which screening they prefer and what
they expect of the early detection by the screening tools.
Results: 255 (62%) women completed our questionnaire. The high chance of early cancer detection was
the most important advantage of MRI screening (MRI-group: 95%; mammography-group: 74%), while
this was also the main advantage of mammography (MRI-group: 57%; mammography-group: 72%). Most
important disadvantages of MRI were the small tunnel and the contrast fluid (for 23e36%), and of
mammography were its painfulness and X-radiation (for 48e60%). Almost the whole MRI-group and half
the mammography-group preferred screening with MRI (either alone or with mammography).
Discussion: Most women would prefer screening with MRI. The way women think of MRI and
mammography is influenced by the screening strategy they are undergoing. Our outcomes can be used
for creating information brochures when MRI will be implemented for more women.
© 2021 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Breast cancer is the most common cancer among women. Many
countries offer breast cancer screening in order to detect breast
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ier Ltd. This is an open access articcancer screening with mammography and/or MRI outside
population-based screening programs [1e3]. Recently, research on
MRI screening efficacy is extended to other subgroups of women
with increased risk. A large randomized controlled trial in women
with extremely dense breast tissue in the population-based
screening program showed that additional MRI led to less inter-
val cancers [4]. Another randomized controlled trial, investigating
MRI screening in women with a family history of breast cancer but
without a pathogenic gene variant (the FaMRIsc trial), also showed
a higher sensitivity of MRI, and cancers being detected at an earlier
stage, compared to mammography [5]. Unfortunately, MRI
screening also leads to more false positive screening results, whichle under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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mammography [8,9].
Whether women should be screened with MRI is mostly based
on cohort studies, randomized controlled trials and cost-
effectiveness analyses. Little is known about preferences of
women themselves. However, participant acceptability is crucial
for a possible implementation of MRI screening. Due to the above-
mentioned randomized trials, and increasing MRI expertise and
technologic advances over the years, it is possible that this modality
will be implemented for a greater amount of women in the future
[10].
Several studies on population-based mammography screening
showed that women regard the possibility of an earlier diagnosis as
more important than the risk of false-positive screening results or
overdiagnosis [11]. A study by Phillips et al. investigated patient
preferences and attitudes towards contrast-enhanced spectral
mammography (CESM) and MRI, and found that most high-risk
women in their study preferred CESM over MRI if the exams had
equal sensitivities [12]. Another study also showed a preference
towards CESM overMRI [13]. In contrast, a study by Essink-Bot et al.
showed that women with an increased risk for breast cancer un-
dergoing MRI screening mainly preferred MRI as a screening test
over mammography when assuming equal performance [14]. They
also showed that these women experienced ‘lying in the tunnel’,
‘noise of the machine’ and the fact that they were not allowed to
move during the procedure as important burdens of MRI [14]. To
our knowledge, no previous studies investigated what womenwho
were randomized to either MRI or mammography screening expect
and think of both tools.
In our study, we compare experiences, expectations and pref-
erences for MRI and mammography among women with a family
history of breast cancer who were either screened with
mammography or with a combination of MRI and mammography
during the FaMRIsc trial [5,15].
2. Methods
2.1. Study population
The Familial MRI Screening (FaMRIsc) trial was a multicenter
randomized controlled trial assessing the efficacy of MRI screening
in comparison to mammography inwomenwith a family history of
breast cancer, and assessing the influence of breast density [15].
Women aged 30e55 years with a cumulative lifetime risk for breast
cancer of 20% due to a family history without a known BRCA1/2 or
TP53 variant were randomly assigned to two groups: 1) the
mammography-group: screening consisting of annual mammog-
raphy, and 2) the MRI-group: screening consisting of annual MRI
and biennial mammography. Both groups also received annual
clinical breast examination (CBE). Women who did not want to be
randomized but who provided consent for registration of their
screening results were grouped as the registration group (231/
1586 ¼ 15%) and could either be screened according to the
mammography-protocol (218 of 231 ¼ 94%) or MRI-protocol (13 of
231 ¼ 6%) [15]. In this paper, all women who were screened ac-
cording to the MRI-protocol are referred to as the MRI-group, and
women screened according to the mammography-protocol are
referred to as the mammography-group.
During the final months of the FaMRIsc trial (end of 2017), 412 of
1586 (26%) participants were sent a letter inwhich theywere asked
to complete a questionnaire [15]. The letter contained a code to log
in to a website to complete the questionnaire. Participants could
also request a printed version of the questionnaire. The invitation
letter for the questionnaire was sent randomly to an equal number
of women per screening protocol who filled in a previous2
questionnaire. This was done to increase the likelihood of reaching
a high response rate. We aimed to also include all women with a
breast cancer diagnosis, so we also invited participants who were
diagnosed with an invasive cancer during the trial. In the letter we
highlighted that we were not testing their knowledge but that we
were interested in their opinion.
2.2. Questionnaire
The questionnaire was developed by three researchers of the
FaMRIsc study (of which one was also a clinician) and was dis-
cussed in a group of five other breast cancer screening researchers.
The questionnairewas sent towomen in November 2017. In January
2018, a reminder was sent to all womenwho did not respond to the
first invitation.
The questionnaire contained 17 questions and an open space to
fill in the year of birth. The questions included in this paper
encompassed four categories: 1) breast cancer (screening) history;
2) advantages and disadvantages; 3) expectations; 4) preference.
The questionnaire can be found in the Supplementary Appendix.
Questions 1e4 were related to the history of breast cancer
screening and a possible breast cancer diagnosis. The category
‘advantages and disadvantages’ consisted of four questions (ques-
tions 11, 12, 13 and 14), all containing a list of advantages or dis-
advantages of MRI or mammography screening. In these questions,
participants were asked to assign all options from the list that they
consider important advantages or disadvantages of MRI and
mammography. In case multiple answers were chosen, participants
were asked to indicate which answer was most important to them.
The category ‘expectations’ contained a question about screening in
general (question 5), a question about early detection of MRI in
comparison with mammography (question 10), and two questions
about trust in the findings of mammography and MRI (questions 8
and 9), both on a Likert scale with a range of 0e4. The category
‘preference’ contained a question to obtain participants’ prefer-
ences for a screening modality and questions evaluating preference
with regard to the ability of early detection, the chance of false-
positive results and costs (question 6, 15, 16 and 17). One ques-
tionwas neither about mammography orMRI (question 7), and was
therefore not included in this manuscript (but the outcomes can be
found in the Supplementary appendix, table S9).
2.3. Statistical analyses
Outcomeswere stratified according to the screening protocols of
the study: the MRI-group and the mammography-group. Further-
more, outcomes of the preference for a screening modality (ques-
tion 6) were stratified by women experiencing a false alarm yes/no
(question 3), and by womenwho had ever had undergone MRI yes/
no (question 4) when participating in the mammography-group.
The latter stratification was also performed for the question about
trust in the findings of MRI (question 9). Fisher’s exact tests were
performed to examine differences in the answers between the
groups. A p-value of 0.05 or less was considered statistically sig-
nificant. Missing data were taken into account when analyzing the
data, and were included in the tables, however these were not
included in the Fisher’s exact tests.
3. Results
A total of 412 participants of the FaMRIsc study were sent a
letter in which we asked them to fill in our questionnaire. After
receiving the first letter, 178 women filled in the questionnaire, and
another 77 women filled it in after the reminder was sent. This
resulted in a response rate of 62% (255/412). Two women did not
H.A. Geuzinge, E.A.M. Heijnsdijk, I.-M. Obdeijn et al. The Breast 56 (2021) 1e6answer the question regarding the screening protocol they were
assigned to. Therefore, we excluded the outcomes of these two
women from the analyses. Of the respondents, 43% (108/253) was
screened according to the MRI-protocol, and 57% (145/253) ac-
cording to themammography-protocol. Most of thesewomen (241/
253: 95% underwent randomization to these protocols, and the
other 12 women participated in the registration group. Of the
women who were screened according to the mammography-
protocol, 36% (49/145) previously had a breast MRI, either for di-
agnostics or for screening. Women in the MRI-group were on
average 50 years old (SD:6.3), and women in the mammography-
group 51 years old (SD:6.4). Seven respondents were diagnosed
with breast cancer (MRI-group: 5; mammography-group: 2), of
which six were screen-detected within the FaMRIsc study, and one
was an interval cancer. Four women were diagnosed with a pre-
cursor of breast cancer (ductal carcinoma in situ) before the FaM-
RIsc study, and two women were undergoing additional diagnostic
testing due to a positive screening result (both in the MRI-group).
All outcomes of the questions regarding breast cancer (screening
history) can be found in the supplementary appendix (tables S1-
S4).
3.1. Advantages and disadvantages
Table 1 shows how often specific advantages and disadvantages
of mammography and MRI were chosen per group. In the MRI-
group more women called ‘the high chance of early detection’ an
advantage or MRI than of mammography (95% vs. 57% respec-
tively), while in the mammography-group the advantage of ‘high
chance of early detection’ was given as frequently for MRI as for
mammography (74% vs 72% respectively). In both groups, the high
chance of early detection was the most frequently mentionedTable 1
Advantages and disadvantages of mammography and MRI.





High chance of early detection of
breast cancer
61 (57%) 105 (72%) It
You can get the screening result
quickly
58 (54%) 98 (68%) Y
It does not take much time 43 (40%) 67 (46%) It
I was already familiar with
mammography
30 (28%) 46 (32%) I
m
It has a small chance of a false alarm 14 (13%) 20 (14%) It
I can get it close to where I live 9 (8%) 17 (12%) O
I do not see advantages of
mammography
10 (9%) 10 (7%) It
It is not expensive 8 (7%) 8 (6%) It
Other, … 9 (8%) 7 (5%) I
Advantages of MRI MRI-group
(N ¼ 108)
Mammography-
group (N ¼ 145)
Disadvantages o
High chance of early detection
of breast cancer
103 (95%) 107 (74%) You have to lie i
You don’t get X-radiation 43 (40%) 60 (41%) The infusion of c
It does not cause pain 45 (42%) 55 (38%) The noise is unp
You can get the screening
result quickly
19 (18%) 33 (23%) It takes a lot of t
It has a small chance of a false
alarm
27 (25%) 21 (15%) I do not see disa
Other, … 1 (1%) 20 (14%) Other, …
I can keep some clothes on 7 (7%) 6 (4%) I have to wait m
Some contrast flu
side effects of th
It is expensive
It does not detec
It causes a false
It is far from hom
3
advantage for both mammography and MRI. The two groups also
agreed on the most important disadvantages of mammography
screening: 1) ‘it is painful’, 2) ‘radiation risk’, and 3) ‘it does not
detect all breast cancers’. Women who chose the option ‘Other, …’
for the questions about advantages and disadvantages of MRI,
mostly wrote that they never had a breast MRI and therefore did
not know what to answer. The disadvantage ‘it causes a false alarm
sometimes’ was not frequently chosen, neither for MRI nor for
mammography (percentages ranging from 5% to 20%).
When asking the participants to indicate which advantage and
disadvantage of mammography screening was most important for
them, most women ranked the chance of early detection by
mammography as the most important advantage (mammography-
group: 65% (67/103); MRI-group: 53% (39/74)), and the fact that
mammography can be painful as the most important disadvantage
(mammography-group: 41% (46/111); MRI-group: 29% (23/80)).
Women of the MRI-group ranked the disadvantages ‘radiation risk’
and ‘it does not detect all breast cancers’ also as important disad-
vantages of mammography, with 26% (21/80) and 28% (22/80)
respectively. When it comes to advantages of MRI, both groups
ranked the early detection of breast cancers as most important
(mammography-group: 60% (61/101); MRI-group: 81% (69/85)).
The groups also agreed on themost important disadvantage ofMRI:
‘you have to lie in a small tunnel’ (mammography-group: 26% (24/
91); MRI-group: 24% (20/85)).
Percentages are calculated with the number of women as de-
nominator. Since women were allowed to choose more than one
option, the sum of all percentages is higher than 100%.
3.2. Expectations




is painful 65 (60%) 83 (57%)
ou get X-radiation 52 (48%) 71 (49%)
does not detect all breast cancers 52 (48%) 46 (32%)
do not see disadvantages of
ammography
16 (15%) 29 (20%)
causes a false alarm sometimes 22 (20%) 26 (18%)
ther, … 4 (4%) 6 (4%)
takes long before I get the result 1 (1%) 5 (3%)
takes (too) much time 0 1 (1%)




group (N ¼ 145)
n a small tunnel 39 (36%) 47 (32%)
ontrast fluid is unpleasant 35 (32%) 34 (23%)
leasant 35 (32%) 31 (21%)
ime 27 (25%) 22 (15%)
dvantages of MRI 26 (24%) 19 (13%)
10 (9%) 41 (28%)
ore than one day for the result 20 (19%) 14 (10%)
id may remain in my body, even though no
is are known
16 (15%) 12 (8%)
10 (9%) 18 (12%)
t all breast cancers 12 (11%) 12 (8%)
alarm sometimes 11 (10%) 7 (5%)
e which causes travel time 3 (3%) 2 (1%)
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without screening (see appendix). Similar proportions of both
groups thought that MRI has a higher chance of detecting breast
cancer in an early stage than mammography (MRI-group: 84%;
mammography-group: 81%). However, more women of the MRI-
group thought that MRI has a much higher chance of detecting
breast cancer in an early stage than women of the mammography-
group (Table 2). The difference in expectationwas statistically non-
significant (p ¼ 0.098).
In total, 85% of the MRI-group and 92% of the mammography-
group had quite some trust or a lot of trust in mammography
screening (Table 3). The proportion of women with a lot of trust in
mammography was relatively large in the mammography-group,
compared to the MRI-group (57% versus 37%). The difference in
trust in mammography was statistically significant (p ¼ 0.014)
between the groups. Higher proportions of women had a lot of trust
in MRI, compared to mammography. However, a similar proportion
of the mammography-group had a lot of trust in MRI (61%) as they
had in mammography (57%). A relatively high proportion of the
MRI-group had a lot of trust in MRI compared to the
mammography-group (82% versus 61%). The difference in trust in
MRI was significantly different (p < 0.001) between the groups.
Subgroup analyses of trust in the findings of MRI, stratified by prior
experience with MRI are shown in Table S5. A higher proportion of
womenwho had prior experience with breast MRI had a lot of trust
in MRI (38/49: 78%) than women who never had a breast MRI (45/
89: 51%).3.3. Preference
Preference for a screening strategy varied significantly per
screening group (p < 0.001), as shown in Table 4. Relatively few
women of the MRI-group (6%) preferred screening with only
mammography, and 31% of the mammography-group preferred
this strategy. Half of the MRI-group (54 of 108) and approximately a
third of the mammography-group (50 of 145) preferred screening
with both MRI and mammography.
Subgroup analyses of preference bywomenwho ever had a false
alarm and those who had not, are shown in Table S6. Women
within the mammography-group who ever had a false alarm, had
slightly less often a preference for mammography only (27%),
compared to women who never had a false alarm within the
mammography-group (33%). Women within the MRI-group who
ever had a false alarm had more often a preference for screening
with MRI only (45%) compared to women who never had a false
alarm (34%) in the MRI-group. It is important to mention that in
these analyses we do not know by which screening tool
(mammography orMRI) false alarms were caused in theMRI-group
because the questionnaire was anonymous.
Table S7 shows the preference outcomes stratified by prior
experiencewithMRI of women in themammography-group. Of the
women having prior experience with MRI, 18% had a preference for
MRI screening and 39% preferred a combination of mammographyTable 2
The chance of detecting breast cancer early by MRI is […] thanwith mammography.
MRI-group (N ¼ 108) Mammography-group (N ¼ 145)
Much smaller 0 1 (1%)
Smaller 2 (2%) 2 (1%)
Similar 15 (14%) 22 (15%)
Slightly higher 39 (36%) 69 (48%)
Much higher 52 (48%) 48 (33%)
Missing 0 3 (2%)
4
and MRI. Of the women not having prior experience with MRI, also
18% had a preference for MRI, and 30% preferred a combination of
mammography and MRI.
Answers to questions 15 and 16 showed that most women (i.e.
36-39%) in the MRI-group preferred screening with MRI regardless
of how much better the early detection or the chance of getting a
false-positive result are (see Tables S10, S11). 41% of the Mx-group
preferred MRI screening in case MRI would case a false alarm as
often asmammography. Only a fewwomen (11e15%) preferredMRI
screening if it causes a false alarm two or three times as often as
mammography. Question 17 showed that for most women
(approximately 75%), their preference for MRI or mammography
seemed not influenced by its costs.
4. Discussion
Women who were screened with both MRI and mammography
had a different view on these screening tools than women who
were screened with mammography only. A higher proportion of
women in the MRI-group valued the advantage of the high chance
of early detection of MRI important compared to women in the
mammography-group. Also, more women of the MRI-group
thought that MRI has a much higher chance of detecting breast
cancer in an early stage than women of the mammography-group.
Furthermore, women screened with MRI plus mammography were
having less trust in the results of a mammogram and more trust in
the results of MRI than women screened with mammography only.
The preference for screening strategy differed also between the two
groups: almost all women of the MRI-group preferred screening
with either MRI only or a combination of MRI and mammography,
whereas half of the mammography-group preferred a screening
strategy with MRI. Most participants in our study understood the
aim of screening very well and indicated the early diagnosis of
breast cancer by mammography and MRI as the most important
advantage. This is in linewith previous studies inwomen at average
breast cancer risk when choosing between mammography and no
screening, showing that early diagnosis is of most importance to
them [11]. A previous study, during the early days of MRI screening,
with a sample of 178 high risk women all undergoing mammog-
raphy and MRI, showed that 44% preferred MRI as a screening test
and 14% preferred mammography when equal performance of
these tests was assumed. Furthermore, they showed that 64% of the
participants was completely reassured by a negativeMRI test result,
but only 40% for mammography [14]. In our study, trust in MRI was
higher: 82% and 61% of the MRI-group and mammography-group
respectively had a lot of trust in the findings of MRI. Fewer
women of the MRI-group (37%) had a lot of trust in mammography
compared to the mammography-group (57%).
This study has some strengths and limitations. A strength of this
study is the fact that two groups of women filled in our question-
naire, so answers by women who were screened with MRI and
mammography could be compared with answers by women who
were not screened with MRI. To our knowledge, previous studies
focused on women who were all screened with both screening
modalities. A limitation of this study is the fact that the question-
naire was not pilot tested. Especially in the Mammography-group,
women indicated that they were not able to say what they
thought were advantages and disadvantages of MRI, since they
never had an MRI. By pilot testing the questionnaire we may have
been able to prevent this by stating these questions differently.
Another limitation of our study is the risk of response bias. Women
with a strong opinion onMRI andmammographymay have filled in
the questionnaire more often than women who did not have a
strong opinion. As the response rates were different between the
two groups, a response bias may have been the case in our study. A
Table 3
Trust in the findings of mammography and MRI
Do you trust the finding that you do/do not have breast cancer
after only mammography?
Do you trust the findings that you do/do not have breast cancer
after only MRI?
MRI-group (N ¼ 108) Mammography-group (N ¼ 145) MRI-group (N ¼ 108) Mammography-group (N ¼ 145)
No trust 4 (4%) 2 (1%) 0 0
A little trust 8 (7%) 4 (3%) 2 (2%) 2 (1%)
Neutral 4 (4%) 6 (4%) 1 (1%) 31 (21%)
Quite some trust 52 (48%) 50 (35%) 17 (16%) 13 (9%)
A lot of trust 40 (37%) 82 (57%) 88 (82%) 88 (61%)
Missing 0 1 (1%) 0 11 (8%)
Table 4
Preference of screening modality.
MRI-group (N ¼ 108) Mammography-group (N ¼ 145)
Mammography 6 (6%) 45 (31%)
MRI 41 (38%) 26 (18%)
Mammography and MRI 54 (50%) 50 (35%)
In the national breast cancer screening program 0 5 (3%)
No preference 6 (6%) 8 (6%)
No screening at all 0 0
Other, … 1 (1%) 9 (6%)
Missing 0 2 (1%)
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questionnaire. However, in the literature we found that women
have limited awareness of overdiagnosis [11].
When interpreting the outcomes on respondents perception on
the price of MRI, it is important to mention that costs of the MRI
were provided by the FaMRIsc study. In case women were referred
for further assessment after a positive MRI, insurers were billed for
these costs. In case MRI becomes part of screening guidelines in the
Netherlands, the costs of MRI will also be billed to insurers.
Currently, in the Netherlands, people pay a deductible of at least
385 euros per year, so therefore sometimes womenwill have to pay
for the MRI themselves when MRI is implemented.
Almost all respondents (95%) were randomly assigned to one of
the two screening protocols. In case women did not want to be
screened according to the MRI protocol, we assume they would
have refused randomization. However, we do not know whether
respondents in the Mammography-group would have accepted
MRI screening eventually, and we did not ask this in our ques-
tionnaire. Therefore, we cannot tell which of the disadvantages of
MRI would be reasons for non-participation. A study on reasons for
declining or not completing MRI screening among women with an
elevated breast cancer risk showed that the most important reason
for not undergoing MRI was claustrophobia (11%) [16]. In our study,
we did not use the word ‘claustrophobia’ but the description that
‘you have to lie in a small tunnel’, which was the most important
disadvantage of MRI in both groups.
Outcomes of our study can be used in creating information
brochures for women undergoing MRI screening, or even tailoring
brochures and screening invitations to prior breast MRI screening
experience of the women. The outcomes of our study and the
outcomes of previous studies evaluating reasons for not partici-
pating can be used to inform women, especially those who have
never had a breast MRI. Our findings suggest that women’s
thoughts on MRI screening change after getting MRI screening.
Future research is needed to evaluate the influence of preferences
and perceptions on actual screening attendance outside a clinical
study.5
5. Conclusion
Our outcomes show that women in the FaMRIsc trial who
received MRI screening, have a preference for this screening tool
and that they have a lot of trust in the screening results of MRI.
Women not undergoing MRI screening seem to be positive towards
MRI screening as well but they also had considerable confidence in
mammography screening. Overall, most women would accept a
screening strategy with MRI as this was preferred the most. The
way women think of MRI and mammography as screening tools
depends on the screening strategy they are undergoing.Data availability statement
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